[go: up one dir, main page]

TR200301971T4 - Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri - Google Patents

Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri

Info

Publication number
TR200301971T4
TR200301971T4 TR2003/01971T TR200301971T TR200301971T4 TR 200301971 T4 TR200301971 T4 TR 200301971T4 TR 2003/01971 T TR2003/01971 T TR 2003/01971T TR 200301971 T TR200301971 T TR 200301971T TR 200301971 T4 TR200301971 T4 TR 200301971T4
Authority
TR
Turkey
Prior art keywords
partial
agonists
complete
heterorocyclic
adenosine derivatives
Prior art date
Application number
TR2003/01971T
Other languages
English (en)
Inventor
A. Zablocki Jeff
P. Palle Venkate
Varkhed Kar Vaibhav
Belardinelli Lu�Z
N. Ibrahim Prabha
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Publication of TR200301971T4 publication Critical patent/TR200301971T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Adenosin A1 reseptörü kismi veya tam agonistleri olan ve bu nedenle memelilerde ve özellikle insanlarda kardiyak aktivitesinin modifiye edilmesi, adiposit fonksiyonun modifiye edilmesi, merkezi sinir sistemi bozukluklarinin tedavisi ve diyabetik bozukluklarin ve obesitenin tedavisi için yararli olan N6 heterosiklik 5' modifikasyonlu adenosin türevleri.
TR2003/01971T 1999-12-03 2000-12-01 Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri TR200301971T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/454,136 US6605597B1 (en) 1999-12-03 1999-12-03 Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives

Publications (1)

Publication Number Publication Date
TR200301971T4 true TR200301971T4 (tr) 2004-01-21

Family

ID=23803455

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/03129T TR200103129T2 (tr) 1999-12-03 2000-12-01 Kısmi ya da tam A1 agonistleri-N6 heterosiklik 5'-tio ikameli adenosin türevleri.
TR2003/01971T TR200301971T4 (tr) 1999-12-03 2000-12-01 Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2001/03129T TR200103129T2 (tr) 1999-12-03 2000-12-01 Kısmi ya da tam A1 agonistleri-N6 heterosiklik 5'-tio ikameli adenosin türevleri.

Country Status (25)

Country Link
US (2) US6605597B1 (tr)
EP (1) EP1233973B1 (tr)
JP (1) JP4021195B2 (tr)
KR (1) KR100484988B1 (tr)
CN (1) CN1152042C (tr)
AR (1) AR029199A1 (tr)
AT (1) ATE254133T1 (tr)
AU (3) AU4138701A (tr)
BR (1) BR0016126A (tr)
CA (1) CA2389264C (tr)
CZ (1) CZ20013705A3 (tr)
DE (1) DE60006576T2 (tr)
DK (1) DK1233973T3 (tr)
ES (1) ES2208437T3 (tr)
HK (1) HK1047941A1 (tr)
HU (1) HUP0500455A2 (tr)
IL (1) IL145903A (tr)
MX (1) MXPA01011113A (tr)
NO (1) NO20015373L (tr)
NZ (1) NZ514777A (tr)
PT (1) PT1233973E (tr)
TR (2) TR200103129T2 (tr)
TW (1) TWI249536B (tr)
WO (2) WO2001040243A2 (tr)
ZA (1) ZA200204380B (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
EP2412716A1 (en) * 2002-02-19 2012-02-01 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
AU2003235466C1 (en) * 2002-04-18 2008-03-20 Gilead Palo Alto, Inc. Method for treating arrhythmias
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
KR20050026546A (ko) * 2002-07-29 2005-03-15 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 수용체 작용제를 이용한 심근 관류 조영
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US7163928B2 (en) 2003-02-03 2007-01-16 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
WO2005040174A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
EP1682537B1 (en) * 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
WO2006044856A2 (en) * 2004-10-20 2006-04-27 Cv Therapeuitics, Inc. Use of a2a adenosine receptor agonists
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
NZ568392A (en) * 2005-11-30 2011-07-29 Inotek Pharmaceuticals Corp Purine derivatives and methods of use thereof
KR101494125B1 (ko) * 2006-02-03 2015-02-16 길리애드 사이언시즈, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
US20100048501A1 (en) 2006-03-21 2010-02-25 Heinrich-Heine-Universitat Dusseldorf Phosphorylated A2A Receptor Agonists
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
CA2662278C (en) * 2006-09-01 2011-11-22 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
CN102014959B (zh) 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
CN102056485A (zh) * 2008-04-15 2011-05-11 萨可德公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN101934559B (zh) * 2010-08-12 2013-04-17 中国电子科技集团公司第四十五研究所 具有压力调节机构的砂浆供给装置
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373097A (en) 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
CA2191245A1 (en) * 1994-06-09 1995-12-14 Kazuo Yamazaki 4-quinolinone derivative or salt thereof
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives

Also Published As

Publication number Publication date
DK1233973T3 (da) 2004-02-16
NZ514777A (en) 2004-01-30
US20050054605A1 (en) 2005-03-10
JP4021195B2 (ja) 2007-12-12
AU7938301A (en) 2002-03-21
CZ20013705A3 (cs) 2002-04-17
DE60006576T2 (de) 2004-09-16
US6605597B1 (en) 2003-08-12
IL145903A (en) 2006-04-10
CA2389264A1 (en) 2001-06-07
ES2208437T3 (es) 2004-06-16
CN1152042C (zh) 2004-06-02
JP2003516325A (ja) 2003-05-13
PT1233973E (pt) 2004-02-27
AU1811701A (en) 2001-06-12
TWI249536B (en) 2006-02-21
EP1233973B1 (en) 2003-11-12
KR100484988B1 (ko) 2005-04-22
TR200103129T2 (tr) 2002-10-21
MXPA01011113A (es) 2002-06-04
WO2001040246A1 (en) 2001-06-07
WO2001040243A3 (en) 2001-12-13
EP1233973A1 (en) 2002-08-28
ATE254133T1 (de) 2003-11-15
NO20015373D0 (no) 2001-11-02
AU4138701A (en) 2001-06-12
AU761029B2 (en) 2003-05-29
NO20015373L (no) 2001-11-29
HUP0500455A2 (hu) 2005-08-29
ZA200204380B (en) 2003-06-25
CA2389264C (en) 2007-03-06
DE60006576D1 (de) 2003-12-18
BR0016126A (pt) 2002-08-06
WO2001040243A2 (en) 2001-06-07
KR20030032907A (ko) 2003-04-26
AR029199A1 (es) 2003-06-18
CN1378550A (zh) 2002-11-06
HK1047941A1 (zh) 2003-03-14

Similar Documents

Publication Publication Date Title
TR200301971T4 (tr) Kısmi veya tam A1 agonistler N6 hetorosiklik 5'-Tiyo ikameli adenosin türevleri
TR200201470T2 (tr) N6 heterosiklik 8-modifiye adenosin türevleri.
SE0003984D0 (sv) Adenosin A3-receptormodulatorer
NO20010446L (no) Substituert anilidforbindelser og metoder
TR200000015T2 (tr) Bileşikler ve metodlar
PT1019426E (pt) Agonistas e antagonistas do receptor de adenosina a1
EE04499B1 (et) A1-adenosiiniretseptori agonistid, nende valmistamismeetod ja kasutamine
ATE242259T1 (de) Adenosin a1-rezeptor agonisten
DE69825780D1 (de) Adenosin a1-rezeptor agonisten
TR199901721T2 (tr) Merkezi kanabinoid reseptör antagonistlerinin istah ayarlanmasinda kullanilmasi.
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
PT951282E (pt) Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2
DE59814072D1 (de) Verwendung von Agonisten des zentralen Cannabinoid-Rezeptors CB1
DK1036065T3 (da) Substituerede imidazolderivater med agonistlignende aktivitet ved alfa-2B- eller 2B/2C-adrenerge receptorer
TR199700644T1 (tr) Serotonin-iliskili sistemler üzerinde etkiye sahip bilesikler.
PT745075E (pt) Derivados substituidos em 6 do acido micofenolico com actividade imunossupressora
DE68923048D1 (de) Alpha-Subeinheit des LFA-1-Leukocyt-Adhäsions-Rezeptors.
DK0463592T3 (da) 2,4- og 2,5-substituerede pyridin-N-oxider, fremgangsmåder til deres fremstilling samt deres anvendelse
BRPI0507776A (pt) métodos de modular a atividade de citocina; reagentes relacionados
TR200301062T2 (tr) Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri
ES2168384T3 (es) Derivados de 2-amino-1,2,3,4-tetrahidronaftaleno activos para el sistema cardiovascular.
TR200003356T2 (tr) Kabergolin ve pramipeksol: yeni kullanım biçimleri ve birlikte kullanılmaları.
WO2001007471A3 (en) Cell cycle and proliferation proteins
ATE273390T1 (de) Säugertier edg-7 rezeptor homologen
DK1223930T3 (da) Behandling af dyskinesi